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Abstract
 Infectious diseases have a major impact on morbidity andIntroduction:
mortality in hospital. Microbial diagnosis remains elusive for most cases of
suspected infection which impacts on the use of antibiotics. Rapid advances in
genomic technologies combined with high-quality phenotypic data have great
potential to improve the diagnosis, management and clinical outcomes of
infectious diseases.  The aim of the Bioresource in Adult Infectious Diseases
(BioAID) is to provide a platform for biomarker discovery, trials and clinical
service developments in the field of infectious diseases, by establishing a
registry linking clinical phenotype to microbial and biological samples in adult
patients who attend hospital with suspected infection.
 BioAID is a cohort study which employs deferredMethods and analysis:
consent to obtain an additional 2.5mL RNA blood sample from patients who
attend the Emergency Department (ED) with suspected infection when they
undergo peripheral blood culture sampling.  Clinical data and additional
biological samples including DNA, serum and microbial isolates are obtained
from BioAID participants during hospital admission.  Participants are also asked
to consent to be recalled for future studies. BioAID aims to recruit 10,000
patients from 5-8 sites across England.  Since February 2014 >4000 individuals
have been recruited to the study.  The final cohort will be characterised using
descriptive statistics including information on the number of cases that can be
linked to biological and microbial samples to support future research studies.
Ethical approval and section 251 exemption have been obtained for BioAID
researchers to seek deferred consent from patients from whom a RNA
specimen has been collected. Samples and meta-data obtained through
BioAID will be made available to researchers worldwide following submission of
an application form and research protocol.  
 BioAID will support a range of study designs spanning discoveryConclusions:
science, biomarker validation, disease pathogenesis and epidemiological
analyses of clinical infection syndromes.
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Introduction
Adult infectious diseases have a major impact on morbidity and 
mortality in hospitals worldwide1–3. These trends are driven by 
demographic changes associated with an ageing population, 
widespread use of immunosuppressive therapies and complex 
surgery in routine healthcare, and the emergence of new and 
drug-resistant pathogens. Although the use of molecular diag-
nostics has brought advances in the management of infectious 
diseases4,5, for most cases of infection in hospital the microbial 
cause of unselected febrile illnesses remains elusive. Consequently 
empiric treatment decisions are based on clinical and epidemio-
logical knowledge of infectious disease syndromes. Technological 
advances in genomics, transcriptomics, proteomics and metabo-
lomics combined with high-quality data on clinical phenotype 
have great potential to improve the diagnosis and management 
of infectious diseases. Bio-resources have already been 
established for specific infections such as HIV and HCV6,7. There 
are no other studies, to our knowledge, that set out to recruit 
unselected patients presenting acutely to hospital with suspected 
infection. Few studies have investigated diagnosis of infection 
in the emergency department (ED) population8–10, reflecting the 
difficulty in obtaining samples and consent in the acute setting 
and this creates an imbalance in the ability to undertake research 
in the field of acute infection. Innovation in this field is contin-
gent on access to high-quality clinical data linked to prospective 
collection of biological samples.
BioAID has been established as a registry of unselected 
patients who present to the ED with suspected infectious diseases. 
The Bioresource is part of the Department of Health’s National 
Institute for Health Research Bioresource Programme which 
provides a registry of healthy volunteers and patients who have 
been consented for recall by virtue of genotype or phenotype to 
participate in secondary studies.
Methods and analysis
Aim of the study
BioAID has established a network of UK hospitals which 
provide the infrastructure for infectious disease research by 
linking clinical phenotype to microbial and biological samples. 
This will support the development and evaluation of novel diag-
nostic and risk stratification tools based on the application of 
emerging technologies for biomarker discovery and the conduct 
of clinical trials and service developments. The Bioresource also 
provides a platform for studies which investigate the genetic and 
immunological basis for host susceptibility to infectious diseases, 
which is likely to have a bearing on vaccine development.
Choice of study design
A cohort design with deferred consent was selected due to the 
need to sample patients prospectively, the difficulties associated 
with obtaining genuine informed consent in the ED, and our 
desire to sample an unselected group of patients with suspected 
infectious diseases. Clinical data were extracted by a combina-
tion of medical note review and extraction of data from electronic 
health records deemed to be the most efficient and cost-effective 
method to obtain detailed and reliable information from a large 
number of participants across multiple sites.
Study sites
BioAID was originally established in 2014 in London across 
five National Institute of Health Research (NIHR) Comprehen-
sive Biomedical Research Centres (BRC’s). To date, patients 
are being recruited at two centres (University College London 
Hospital (UCLH) and Imperial College Healthcare NHS 
Trust, ICHT, the latter comprising three main sites with two 
EDs. Queen Elizabeth Hospital Birmingham (QEHB) will 
join BioAID in 2018 establishing a site outside of London. The 
proportion of patients who have blood culture sampling in the 
ED and are subsequently recruited to BioAID is estimated to 
be 15–20% across the ICHT sites and UCLH and the majority 
of these patients have been admitted to hospital. Both sites are 
London teaching hospitals which serve urban and ethnically 
diverse populations. The first samples were collected from 
individuals at UCLH in February 2014.
Patient recruitment and consent
Individuals aged > 16 years with suspected infection are eligible 
for inclusion in BioAID provided they undergo peripheral 
blood sampling for microbial culture, which is part of routine 
clinical assessment, contemporaneous with collection of an 
additional 2.5mL RNA blood sample in the ED, Figure 1. Within 
the following 72 hours, clinical research staff approach all 
participants from whom a RNA sample has been collected in 
order to invite them to take part in the study, provide detailed 
information on the study, and obtain informed written consent. 
Informed consent is sought by telephone from patients who have 
not been admitted to hospital, but have provided a RNA sample, 
as well as those who have been admitted but discharged before 
consent could be obtained. Importantly, informed consent is also 
sought by telephone from the next of kin in the case of patients 
who have died but have provided a RNA sample at the time of 
blood cultures being drawn. Consent is also sought for partici-
pants to be recalled to participate in future research studies. The 
acceptability of this approach was investigated at University 
College London Hospital in the FEVER study11, and was deemed 
to be acceptable to both patients and their relatives.
Collection and retrieval of biological samples
Serum samples obtained as part of routine care at the time of 
admission, but surplus to diagnostic requirements are also retrieved 
for the BioAID collection. DNA and additional RNA sample are 
collected during the patient’s admission to hospital, usually 
within 72 hours (Table 1). RNA samples will be used primarily 
to evaluate host responses to infection at the transcriptional level. 
The paired RNA samples will be used to investigate whether 
the timing of the sample impacts on blood transcriptional 
profiles. Serum samples will be available to evaluate host 
responses to infection by proteomic and metabolomic profiling, 
as well as serological assays and quantitation of cytokine 
responses. DNA extraction provides the opportunity for future 
research studies investigating host genetic variants associated 
with the response to infection. Microbial isolates derived from 
specimens obtained during admission are retrieved from the 
laboratory and stored, laying the foundation for future studies 
of infection surveillance, diagnosis, pathogen evolution and 
genomics, disease pathogenesis and host-pathogen interaction. 
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Figure 1. Collection of data and samples in BioAID.
Table 1. Overview of the sampling in BioAID.
Time since admission Blood sample Volume Use
Presentation RNA preservation tube 2.5mL RNA extraction
Serum (clot activator) 2-4mL Serum analytes 
Acute serum
Throughout hospital stay Various microbiological 
samples
Urine, Stool 
Throat swab, sputum etc. 
Microbe identification
Within 1 week of presentation RNA preservation tube 2.5mL RNA extraction
PAXgene / EDTA 8.5mL/10mL DNA extraction
3 months after presentation RNA preservation tube 2.5mL RNA extraction
Serum (clot activator) 5mL Convalescent serum
Participants are invited to attend the hospital for a follow-up 
visit three months after admission when convalescent serum and 
RNA samples may also be obtained.
Handling of biological samples
RNA samples are collected in TempusTM tubes and transferred to 
the microbiology laboratory with the blood culture samples. If 
deferred consent is obtained, the RNA sample is re-labelled 
with a study identifier in place of the patient identification label. 
If informed consent is not provided specimens are destroyed. 
All RNA and DNA samples are labelled with the study 
identifier and stored at -80°C. Microbial isolates and sera 
obtained from the patient during hospital admission are retrieved 
from the laboratory, re-labelled with the study identifier and 
stored at -80°C. All participants and samples are registered in the 
Bioresource database.
Extraction of clinical data from the medical records
A standardised case reporting form (Supplementary File 1) is used 
by a member of the clinical research team at each site to extract 
data from the medical record and/or data are extracted directly 
from the electronic medical record. This includes demographic 
information (age, gender, ethnicity); vital signs and clinical scores 
at admission; laboratory biomarkers for infection; syndrome 
of infection; antibiotic treatment; microbiological culture results 
and sensitivities for blood and other samples; and clinical 
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outcome (duration of hospital admission, ICD-10 coded diagnosis 
on discharge, admission to intensive care, death). Sample type is 
classified according to the microbiology bench where the sample 
was processed. Antibiotic treatment was classified according to 
the antimicrobial section of the British National Formulary and 
microbiological culture results are classified by species.
Data are transcribed by the research team into the research 
database which has been developed using REDcap electronic data 
capture tools hosted at UCLH and ICHT. REDCap (Research 
Electronic Data Capture) is a secure, web-based application 
designed to support data capture for research studies providing 
1) an intuitive interface for data entry; 2) audit trails for tracking 
data manipulation and export procedures; 3) automated export 
procedures for seamless data downloads to common statistical 
packages; and 4) procedures for importing data form external 
sources12.
Statistical analysis and sample size
BioAID aims to recruit 10,000 patients over 8 years across 5–8 
participating centres. These estimates are based on pilot data 
from the FEVER study at UCLH11. Novel genetic variants 
associated with infection related phenotypes have commonly 
required sample sizes ranging from 1000–5000 individuals in 
order to detect clinically meaningful associations between variant 
and phenotype13. Larger sample sizes would be expected to ena-
ble detection of smaller genetic effects (risk ratios < 2.0). This 
Bioresource would therefore be expected to contribute to such 
studies assessing susceptibility to infection or survival following 
sepsis. Based on preliminary data from the Bioresource, we 
anticipate recruiting approximately 2500 cases of respiratory 
tract infection, 2000 cases of urinary tract infection syndromes 
and 1000 cases with bacteraemia. 
The Bioresource has been established to address a range of 
research questions from discovery science through the clinical 
trials and consequently we have not stipulated a single outcome 
measure. We will first summarise the clinical and epidemio-
logical characteristics of the cohort, specifying the primary 
outcome as the proportion of individuals in whom a microbial 
diagnosis is achieved, stratified by clinical infection syndrome 
(respiratory, urinary tract, skin and soft tissue, systemic with no 
foci of infection). Secondary outcomes will include: estimating 
the sensitivity, specificity, positive and negative predictive values 
of a syndromic diagnosis of infection in the ED compared to 
diagnostic coding at discharge from hospital; identification of 
clinical and epidemiological factors associated with adverse 
outcomes including length of stay, admission to intensive care, 
death; and predictors of bacteraemia. Future studies based on 
data and/or samples from this cohort will be required to submit 
a full proposal and analysis plan before being granted access to 
data and/or samples.
Patient and public involvement
The BioAID protocol was developed with advice from the 
UCL Partnership Public Engagement Patient Panel. This group 
provided particular input on the issue of deferred consent and 
have continued to be involved as members of the BioAID 
Advisory Board.
BioAID governance
BioAID is overseen by an executive committee comprising the 
PI’s from each participating site, and meets quarterly to review 
progress and recruitment and to process applications for access 
to data and samples.
Ethical approvals
A specific aim of BioAID is to obtain RNA samples before 
treatment commences because transcriptional profiles can be 
modified by antimicrobial or other treatments and there is 
increasing interest in host responses as part of diagnosis in 
infection14–16. Given the clinical necessity to initiate treatment for 
patients urgently (typically within 1–2 hours), and the fact that 
patients may have impaired consciousness or be distressed, it is 
rarely possible to obtain genuine informed consent from patients 
before collecting blood for RNA and, should it be possible, 
there would be significant biases in the patients recruited. 
Ethical approval and section 251 exemption have therefore been 
obtained for BioAID researchers to seek deferred consent from 
patients from whom a RNA specimen has been collected (or 
from their relatives/nominated consultee) within 72 hours of 
blood sample collection (REC ref: 14/SC/0008).
Governance, data protection and data management
The BioAID dataset is pseudo-anonymised. Participants are 
allocated a unique identification number (UIN) and at each 
participating site a separate electronic and hard copy file is 
maintained linking the UIN with the patient’s hospital number, 
other identifiers and contact details. The local Principal 
Investigator has access to the linkage codes. The live BioAID 
database is held within the NHS firewall.
Data management and access
The BioAID database will be curated by the research team. 
Histograms will be plotted to investigate the distribution of 
continuous variables and rules will be applied to identify likely 
outliers based on laboratory reference ranges and errors in 
dates and age. Samples collected through the Bioresource and 
associated meta-data will be made available to researchers world-
wide. To qualify for access, an application form including a 
research protocol should be submitted to the study coordina-
tor for consideration by the BioAID Executive Committee 
(m.noursadeghi@ucl.ac.uk). Interested researchers are expected 
to cover the processing costs of sample aliquots from the 
Bioresource. Access to samples will be subject to a material 
transfer agreement. All studies using BioAID data and samples 
will be required to submit annual reports to the Executive 
Committee and a copy of all the derived data must be deposited 
within the BioAID database. Publications arising from use of 
the Bioresource are expected to acknowledge the support of the 
NIHR Biomedical Research Centres and to recognise BioAID 
investigators.
Dissemination of findings
Anonymised data will be made available at the time of peer-
reviewed publications, or by 12 months after completion of the 
project. Raw sequencing, genotyping data and linked metadata 
will be made available through quality controlled public reposi-
tories to maximise their use by the scientific community. 
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Specifically, European Bioinformatics Institute Array Express 
repository, for genome-wide transcriptomic data, and the 
European Bioinformatics Institute Genome-Phenome archive for 
genotypic and phenotypic data. Processed and analysed data sets 
will also be made available through supplementary on-line con-
tent associated with peer-reviewed scientific publications. All new 
computational analysis software that we develop in the course 
of this project will made publicly available on the Bioconductor 
platform. Research findings will be communicated to the sci-
entific community via open access peer reviewed publications 
and presentation at conferences. BioAID investigators will work 
with the UCL-Partnership Public Engagement Patient Panel to 
disseminate research findings to patients and the public.
Study status
Ethical approval was granted for BioAID in February 2014 and 
recruitment began shortly afterwards. To date, > 4000 participants 
have been recruited across two NHS Trusts; a third site will join in 
2018. 
Conclusions
The purpose of BioAID is to support large number of 
collaborative projects and associated research publications. To 
date, BioAID has been used primarily for the development and 
validation of transcriptomic gene signatures for bacterial 
infection7, but the sample collection also provides unprecedented 
opportunities to evaluate proteomic and metabolomic biomar-
kers. In the future, there is scope to use BioAID as a recruiting 
framework for inpatient clinical trials or as a means of 
identifying candidates for studies investigating host susceptibility 
to infection or host-pathogen interactions. As the number of sites 
participating in BioAID increases it is anticipated that there will 
be a range of applications to use this dataset.
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MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow, G61 8QQ, UK
The BioAID resource provides a much needed biocollection of well-curated prospectively collected
biological samples from patients presenting to one of several large teaching hospitals with a suspected
infection syndrome. Importantly, samples will be obtained at presentation alongside blood cultures often
prior to the administration of antimicrobial therapy.
It aims to provide researchers with access to large numbers of samples providing a route to meaningful
studies of biomarker identification, host genetics and pathogen identification. The scale of the resource
will mean that genetic associations with outcome will be sufficiently powered for meaningful interpretation.
Judging by the listed authors, the design and the stated broad aims, the current focus appears to be to
address bacterial infection, initially aiming to identify 2500 cases of respiratory infection, 2000 cases of
UTI and 1000 cases of bacteraemia. However, the potential for identification of other pathogens, for
example viral pathogens is also present.
Minor suggestions
Unfortunately, the case reporting form (Supplementary Figure 1) is not available for review (weblink
error) but is likely to provide essential follow-up information on patient demographics and
symptoms as well as outcome. I assume it will also include a travel history.
While it is clear that “microbial isolates and sera obtained from the patient during admission” will be
retrieved, there might also be an opportunity to gather other relevant samples e.g. CSF or urine
which could be used for pathogen discovery at a later date. Sputum and respiratory samples from
the 2500 cases of respiratory infection would allow a search for viral as well as bacterial pathogens
and identification of co-infections.
The ethics for the collection of samples is carefully considered and appropriate with prospective
collection and retrospective approval (in the case of death by the next-of-kin). I wonder, however, if
the possibility of returning results to the relevant patient has been discussed. I am referring, in
particular, to HIV (and other chronic viral infections such as HCV and HTLV) which are likely to be
identified if RNA sequencing is planned. There may be a role for returning such a result to the
patient following clinically validated testing.
Summary
In summary, this is an exciting, large-scale, unique and much needed bioresource with the potential to
unite advances in metabolomics and genomics with clinical pathogen diagnosis, host susceptibility and
identification of predictive biomarkers of disease. It is highly likely to provide a platform for the
development of multiple meaningful studies and will facilitate the introduction of technological advances
into the health service to directly improve patient care.
Is the rationale for, and objectives of, the study clearly described?
Yes
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 Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Next generation sequencing, clinical infectious diseases
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Page 10 of 10
Wellcome Open Research 2018, 3:97 Last updated: 01 OCT 2018
